Launched in Q2 2021 as an affiliate of Cambridge Science (CSC), Kyttaro Ltd is a UK-based pure-play biotech company that plans to develop innovative biologics to treat ASCVD and related metabolic and inflammatory conditions.
Cardiovascular disease, the world’s leading cause of death, has been underinvested for decades by the biopharmaceutical industry. The recent discovery of novel genetically validated Atherosclerotic Cardiovascular disease (ASCVD) targets, new therapeutic modalities and the pivotal CANTOS trial, which established the efficacy of anti-inflammatory therapy in ASCVD, has the therapeutic class on the precipice of a new era in research and development. Despite aggressive glycemic and LDL-C control, primarily through incretins and statin therapeutics, there remains a significant unmet need for high-risk ASCVD patients.
Kyttaro aims to tackle several ASCVD risk factors such as triglycerides (TGs), cholesterol and inflammation. The company plans to complement the anti-inflammatory peptide technology platform with multiple advanced first-in-class biologics that lower TGs and/or improve cholesterol levels to reduce ASCVD.
Kyttaro’s clinical strategy focuses on rare and severe diseases associated with ASCVD risk factors related to TG and cholesterol levels as well as inflammation to establish safety and efficacy and ensure early market access and commercial success. Once Kyttaro establishes the efficacy of the assets in these rare and severe disorders, the company plans to enter the much larger ASCVD market through pharma partnerships to save people.
Douglas Eby – Founder and Chief Executive Officer
Founder and CEO of Cambridge Science, a Kendall Square bioscience company. He is also a co-founder and CEO of Vivtex, a Langer Lab spinout, and in addition to Kyttaro, Mr Eby is a co-founder of several other CSC companies including Ovibio and Kodika. Mr Eby is currently a Senior Fellow at Harvard Law School, where he is leading the Innovative Funding Models for Translational Research Project at the Petrie-Flom Center for Health Law Policy, Biotechnology and Bioethics. He is a former Trustee of Suburban Hospital – Johns Hopkins Medicine.
Alan Ashworth, PhD, FRS – Co-Chair Scientific Advisory Board
President of the UCSF Helen Diller Family Comprehensive Cancer Center, and Sr. Vice President for Cancer Services with UCSF Health. Before joining UCSF in January 2015, he served as Chief Executive of the Institute of Cancer Research (ICR) and the Director of the Breakthrough Breast Cancer Research Centre in London. He discovered how to kill BRCA1-and 2-related tumour cells by treating them with PARP inhibitors which are drugs that increase the damage caused by the broken DNA repair machinery in those cells. Three different PARP inhibitors are now approved by the FDA.
Abhimanyu Garg, MD – Co-Chair Scientific Advisory Board
Chief of the division of nutrition and metabolic disease at the UT Southwestern Medical Center. He is also Director of Metabolic Diseases in the Center for Human Nutrition, Director of the Nutrition and Metabolic Diseases Fellowship Program, and holder of the Distinguished Chair in Human Nutrition Research. Prof Garg is a leading expert on lipodystrophy treatment and research. Dr Garg received his medical degree and completed his residency in internal medicine at the All-India Institute of Medical Sciences.
We are pleased to be joining the flourishing Oxford University bioscience community. The sense of excitement and momentum is palatable. With record resources being committed on the ground and in the lab, against a backdrop of world-class science, the scene reminds me of Kendall Square a few years back. Kyttaro is looking forward to contributing to the critically important acceleration of translational research, which will lead to novel therapeutics treating patients suffering from the disease.
Douglas Eby, Kyttaro Founder and CEO